Flag of the European Union EU Clinical Trials Register Help

Clinical trials for QT prolongation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    49 result(s) found for: QT prolongation. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2016-003521-42 Sponsor Protocol Number: ARG-E08 Start Date*: 2017-02-09
    Sponsor Name:Mitsubishi Tanabe Pharma GmbH
    Full Title: SAICoDis – Safety of Argatroban Infusion in Conduction Disturbances. A prospective, open, multicenter safety study to investigate conduction disturbances in patients receiving argatroban therapy.
    Medical condition: Patients without diagnosed HIT II but with a coronary heart disease and with a diagnosed stable or unstable angina are planned for a percutaneous coronary intervention (PCI) according to clinical r...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003211 Arteriosclerosis coronary artery PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006168-46 Sponsor Protocol Number: P04342 Start Date*: 2006-12-21
    Sponsor Name:Schering-Plough Research Institute
    Full Title: Thorough QT/QTc study for Garenoxacin
    Medical condition: Indication: bacterial infections
    Disease: Version SOC Term Classification Code Term Level
    8.1 10004047 Bacterial infections NEC HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004903-20 Sponsor Protocol Number: ABR-38376 Start Date*: 2012-05-09
    Sponsor Name:
    Full Title: Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trial
    Medical condition: Patients with histologically confirmed stage IV non-squamous non-small-cell lung cancer (NSCLC) • with an activating EGFR mutation who progressed on erlotinib or gefitinib monotherapy. OR • who...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023491-25 Sponsor Protocol Number: MFX468 Start Date*: 2011-01-18
    Sponsor Name:University Medical Center Groningen
    Full Title: Pharmacokinetics and safety of moxifloxacin; a dose escalation in patients with tuberculosis
    Medical condition: Tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10044755 Tuberculosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002314-40 Sponsor Protocol Number: CoV-2_DDI Start Date*: 2020-09-14
    Sponsor Name:Medizinische Universität Wien; Universitätsklinik für Klinische Pharmakologie
    Full Title: A Pilot study platform to investigate the pharmacodynamics on QT‐prolongation and pharmacokinetics after multiple dose administration of potential combination treatments for COVID-19 in healthy vol...
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001976-39 Sponsor Protocol Number: CHDR1227 Start Date*: 2013-07-30
    Sponsor Name:Centre for Human Drug Research
    Full Title: Randomized, open-label, crossover study into the contribution of the intestines and kidney in the diurnal variation of Levofloxacin pharmacokinetics
    Medical condition: The circadian variation in the relative contribution of intestinal uptake and renal elimination of levofloxacin
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001025-28 Sponsor Protocol Number: NuTide:121 Start Date*: 2019-06-06
    Sponsor Name:NuCana plc
    Full Title: A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary T...
    Medical condition: Histologically- or cytologically-confirmed adenocarcinoma of the biliary tract (including gallbladder, intra and extra-hepatic biliary ducts and ampullary cancers) that is locally advanced, unresec...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023185-42 Sponsor Protocol Number: S105AMCNilotinibSpA Start Date*: 2011-04-21
    Sponsor Name:Academic Medical Center, Division of Clinical Immunology and Rheumatology
    Full Title: Proof-of-concept double-blind, placebo-controlled, randomized clinical trial with nilotinib in spondyloarthritis
    Medical condition: Active axial and peripheral spondyloarthritis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000653-32 Sponsor Protocol Number: CFTY720DDE17 Start Date*: 2012-06-27
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 1-week, open-label, multi-center study to explore conduction abnormalities during first dose administration of fingolimod in patients with relapsing-remitting multiple sclerosis (START)
    Medical condition: Conduction abnormalities in patients with relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014377-40 Sponsor Protocol Number: Bay 58-2667/14560 Start Date*: 2010-01-08
    Sponsor Name:Bayer Healthcare AG
    Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenousl...
    Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064653 Acute decompensated heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) AT (Prematurely Ended) SK (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014378-16 Sponsor Protocol Number: Bay 58-2667/14663 Start Date*: 2010-01-14
    Sponsor Name:Bayer Healthcare AG
    Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of Low Dose BAY 58-2667 (25 μg/h, 10 μg/h) Given Intravenously ...
    Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064653 Acute decompensated heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001515-37 Sponsor Protocol Number: C-II-005 Start Date*: 2008-06-11
    Sponsor Name:CESAR Central European Society for Anticancer Drug Research
    Full Title: A prospective angiogenic imaging study with DCE-MRI and DCE-USI in patients with colorectal cancer and liver metastases receiving sunitinib in addition to 5-FU, folinic acid and irinotecan (FOLFIR...
    Medical condition: metastatic colorectal carcinoma with liver metastases
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002584-70 Sponsor Protocol Number: 155-CL-009 Start Date*: 2007-09-14
    Sponsor Name:Astellas Pharma US, Inc.
    Full Title: A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
    Medical condition: Diffuse large B-cell Lymphoma refractory
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003077-15 Sponsor Protocol Number: EIG-LNF-002 Start Date*: 2015-11-23
    Sponsor Name:Eiger BioPharmaceuticals
    Full Title: A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of Titrating-Dose Lonafarnib in Combination with Ritonavir in Patients Chronically Infected w...
    Medical condition: Chronic Hepatitis D Virus (HDV) Infection.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017082-39 Sponsor Protocol Number: Bay 58-2667 / 14836 Start Date*: 2010-02-01
    Sponsor Name:Bayer Healthcare AG
    Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 μg/h, 100 μg/h, 150 μg/h) Given Intravenousl...
    Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064653 Acute decompensated heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) IE (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-001888-23 Sponsor Protocol Number: TV7820-CNS-20002 Start Date*: 2014-03-25
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc
    Full Title: A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus...
    Medical condition: Huntington’s disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) NL (Completed) AT (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-010788-18 Sponsor Protocol Number: CAMMS03409 Start Date*: 2009-07-01
    Sponsor Name:Genzyme Corporation
    Full Title: An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) SE (Completed) AT (Completed) PL (Completed) CZ (Completed) NL (Completed) DK (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003364-19 Sponsor Protocol Number: AI424376 Start Date*: 2009-01-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multicenter, Randomized, Open-Label, Active-Controlled Pilot Study to Evaluate the Safety and Antiretroviral Activity of Unboosted Atazanavir BID Plus Raltegravir BID and Boosted Atazanavir QD in...
    Medical condition: HIV, COMBINATION THERAPY
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-010143-13 Sponsor Protocol Number: C-II-006 Start Date*: 2009-06-03
    Sponsor Name:CESAR Central European Society for Anticancer Drug Research-EWIV
    Full Title: Prospective randomized phase-II trial with Temsirolimus versus Sunitinib in previously untreated patients with advanced or metastatic non-clear cell renal carcinoma
    Medical condition: advanced or metastatic non-clear cell renal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003257-42 Sponsor Protocol Number: ACH-CYT-02 Start Date*: 2017-10-03
    Sponsor Name:Achieve Life Sciences Inc
    Full Title: Repeat-Dose Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers
    Medical condition: Smoking cessation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:48:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA